Members of the ACCC IO Institute Executive Committee discuss why it’s essential to accommodate the unique side-effect profile for immunotherapy patients in survivorship care plans. (features Linda House, RN, BSN, MSM; and Jennie Crews, MD, MMM, FACP)
![[Publication] Immuno-Oncology in 2020: What We’ve Learned and What Lies Ahead](https://cdn.sanity.io/images/0vv8moc6/accc-cancer/bfe59825abe0dd1669260c33c2931629f9328774-258x333.png)
This new white paper explores the most recent ACCC resources to meet the evolving needs of the multidisciplinary care team and describes next steps for supporting optimal IO care delivery.
Immune-related adverse events (irAEs) are a complex category of symptoms driven by anti-cancer immunotherapy treatments. The use of IO has burgeoned since the approval of ipilimumab in 2011 through multiple approvals of anti-PD-1/PD-L1 drugs and most recently CAR-T therapies, and so too has the number of recognized irAEs.
Survivorship care planning requires communication, care coordination, and education. Since immune-related adverse events are still being discovered, these discussions are even more imperative.
As immune checkpoint inhibitors have become the standard of care for eligible patients with NSCLC, frequent monitoring of irAEs as well as provider and patient education on the signs and symptoms of pneumonitis can ensure improved clinical outcomes for patients.
June is Cancer Immunotherapy Month, and ACCC is highlighting the important work that it and its partners are doing to increase patient access to these novel therapies.
Explore strategies to improve communication, build trust, and improve relationships between clinicians and administrators, ensuring the creation of safe and supportive environments for both team members and patients.
After realizing that a growing number of patients with cancer experienced significant delays and denials in home care and hospice services, Shaw Cancer Center built an oncology-specific home- and community-based palliative care program from the ground up.
Explore the current landscape, unique challenges, emerging trends, and strategic considerations for women’s oncology, and understand the importance of coordinated, multidisciplinary care models.
This article explores the exciting potential for pharmacists in the cardio-oncology setting, where their knowledge of oncolytic therapies, drug interactions, and toxicity management proves integral to patient care.